Almac Discovery
@almac_discovery
Craigavon, Non-US/Otherhttp://www.almacgroup.com/discovery Biotechnology ResearchOverview
About Almac Discovery
Passionate about oncology
Almac Discovery enjoys the challenge of first-in-class and best-in-class projects (view our pipeline). The combination of the highest quality science and dedicated, passionate people position Almac Discovery as a partner of choice in the challenging world of modern drug discovery.
We work creatively and energetically with all of our collaborators, industrial and academic, to translate early stage research from concept to therapeutic.
Headquartered in Craigavon, Northern Ireland our research laboratories are based in the Centre for Precision Therapeutics in the heart of the life sciences and hospital campus at Queen’s University, Belfast. Our goal is to provide high quality oncology programmes in areas of unmet need and to develop those programmes with our partners and collaborators. We currently have active research in ubiquitin specific proteases and protein drug conjugates.
Access to the extensive capabilities in pharmaceutical development available through our parent company, the Almac Group, enables us to engage in clinical stage oncology discovery and development . Currently, our lead programme, ALM201, is in clinical development.
Within Almac Discovery we have developed a passionate and experienced team whose drive and commitment enables us to take forward highly innovative and challenging partnering opportunities.
Almac Discovery enjoys the challenge of first-in-class and best-in-class projects (view our pipeline). The combination of the highest quality science and dedicated, passionate people position Almac Discovery as a partner of choice in the challenging world of modern drug discovery.
We work creatively and energetically with all of our collaborators, industrial and academic, to translate early stage research from concept to therapeutic.
Headquartered in Craigavon, Northern Ireland our research laboratories are based in the Centre for Precision Therapeutics in the heart of the life sciences and hospital campus at Queen’s University, Belfast. Our goal is to provide high quality oncology programmes in areas of unmet need and to develop those programmes with our partners and collaborators. We currently have active research in ubiquitin specific proteases and protein drug conjugates.
Access to the extensive capabilities in pharmaceutical development available through our parent company, the Almac Group, enables us to engage in clinical stage oncology discovery and development . Currently, our lead programme, ALM201, is in clinical development.
Within Almac Discovery we have developed a passionate and experienced team whose drive and commitment enables us to take forward highly innovative and challenging partnering opportunities.